Vasoactive intestinal peptide release from microparticles
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsSteven R. Little, Andrew Jason Glowacki
Life of this patent
Estimating the term…
Abstract
Controlled release of VIP from PLGA microparticles was accomplished and varied through use of different polymer molecular sizes, addition of solutes to the inner aqueous phase, and use of our computer model. Released VIP from microparticles appeared to be bioactive and caused DCs to produce more CCL22 than DCs treated with blank particles at 7 and 24 hours. Additionally, DCs treated with VIP microparticle releasates recruited higher percentages of FoxP3+ T-cells in in vitro chemotaxis studies. Testing in a mouse model in vivo indicated that VIP microparticles have significant therapeutic potential to treat periodontal disease by reducing the bone loss in infected mice relative to the blank group.
Claims15
A method of preparing a microparticle, comprising:
- a) obtaining a solution comprising an organic solvent, a vasoactive intestinal peptide (VIP), a polyethylene glycol, and at least one polymer, wherein the at least one polymer is selected from the group comprising a polylactide-co-glycolide (PLGA) polymer, an RG502H polymer, an RG505 polymer, or a combination thereof;
- b) emulsifying the solution to obtain the microparticle;
- and
- c) immobilizing in the microparticle a surface bound Treg stimulatory factor, a surface bound osteoclast signaling factor, or a combination thereof.
Dependencies are inferred from the claim text.